|Bid||43.24 x 800|
|Ask||73.95 x 800|
|Day's Range||42.60 - 44.47|
|52 Week Range||42.60 - 85.66|
|Beta (3Y Monthly)||1.67|
|PE Ratio (TTM)||23.95|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||57.00|
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Eagle Pharmaceuticals, Inc. (EGRX) (“Eagle” or the “Company”) today announced positive results of a proof-of-concept (POC) study in a Total-Body Radiation Animal Model. The objective of the study was to evaluate the efficacy of intravenous administration of RYANODEX® to prevent or mitigate Acute Radiation Syndrome (ARS) in a total body irradiated C57BL/6 male mouse hematopoietic model.
Does the November share price for Eagle Pharmaceuticals Inc (NASDAQ:EGRX) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value by estimating the company’s future cash flows and Read More...
Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will pre
Eagle Pharmaceuticals (EGRX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 0.00% and 0.86%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Woodcliff Lake, New Jersey-based company said it had profit of 91 cents per share. Earnings, adjusted for non-recurring costs, were $1.18 per share. The specialty pharmaceutical company posted revenue ...
-- Q3 2018 net income was $0.94 per basic and $0.91 per diluted share and adjusted non-GAAP net income was $1.22 per basic and $1.18 per diluted share --
-- Q3 2018 preliminary EPS is expected to be $0.94 per basic and $0.91 per diluted share --
Eagle Pharmaceuticals, Inc. (EGRX) (“Eagle” or the “Company”) today announced that the Company’s fulvestrant formulation has not met the primary bioequivalence endpoints evaluating Eagle’s formulation compared to FASLODEX® in its open label, randomized, pharmacokinetic (PK) and safety study conducted in 600 healthy female volunteers across multiple U.S. sites. The Company will continue to evaluate the data, but as a result of this outcome, Eagle intends to focus on advancing the development of other products in its pipeline.
Eagle Pharmaceuticals, Inc. today announced that the Company will release its 2018 third quarter financial results on Thursday, November 1, 2018, before the market opens.
NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to begin learning about how to Read More...
Eagle Pharmaceuticals, Inc. (EGRX) (“Eagle” or the “Company”) today announced that it has entered into an agreement with the United States Army Medical Research Institute of Chemical Defense (USAMRICD), the nation's leading science and technology laboratory in the area of medical chemical countermeasures research and development, to conduct a study to evaluate the neuroprotective effects of RYANODEX® (dantrolene sodium). The study will be conducted under a Cooperative Research and Development Agreement (CRADA), a written agreement that allows government laboratories to partner with private industries or academia on research and development projects.
Eagle Pharmaceuticals, Inc. announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will pr
Eagle Pharmaceuticals, Inc. today announced that the Compensation Committee of the Company’s Board of Directors has approved the appointment of David Pernock to the position of Chief Operating Officer, effective as of September 1, 2018.
If you own shares in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...